Influencing Factors and Prediction Model of False-negative Central Lymph Nodes in Thyroid Cancer Patients
Launched by NINGNING REN · May 15, 2024
Trial Information
Current as of February 19, 2025
Completed
Keywords
ClinConnect Summary
Setting and Population This study collected 6369 patients admitted to the Breast and Thyroid Surgery Department of Shandong Provincial Hospital between January 2013 and December 2023, who were diagnosed with TC through postoperative pathology. (SDC, Figure 1) All patients included in the study signed a written informed consent form before surgery. Ethical approval for this study (NO.SWYX2024-225) was provided by the Ethical Committee of Shandong Provincial Hospital, Jinan, China on 15 April 2024. According to the relevant literature, the criteria for identifying abnormal cervical LN under u...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. All cases are new cases of thyroid cancer.
- • 2. All clinical data and research materials of the cases are complete.
- • 3. All cases underwent preoperative thyroid and neck lymph node examinations by the Ultrasound Department of Shandong Provincial Hospital.
- • 4. All cases showed no swelling in the central lymph node status on preoperative ultrasound.
- • 5. All cases underwent initial surgical treatment.
- • 6. All cases were diagnosed with thyroid cancer through postoperative pathological examination.
- Exclusion Criteria:
- • 1. Except for cases of recurrence.
- • 2. Cases with incomplete clinical data and research materials are excluded.
- • 3. Cases that have not undergone thyroid and neck lymph node examination by the ultrasound department of Shandong Provincial Hospital before surgery are excluded.
- • 4. Cases with enlarged lymph nodes in the central thyroid region indicated by preoperative ultrasound are excluded.
- • 5. Excluding cases of secondary surgery.
- • 6. Cases with postoperative pathological diagnosis of benign thyroid tumors are excluded.
About Ningning Ren
Ningning Ren is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing novel therapeutic solutions, the organization collaborates with leading healthcare professionals and research institutions to design and implement rigorous clinical trials. Ningning Ren prioritizes patient safety and ethical standards while striving to bring cutting-edge treatments to market. Their team of experts is driven by a passion for improving health outcomes and enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0